Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
No crowded waiting rooms, no rushing through traffic - just professional, personalized care in your own space
It has no withdrawal syndrome and no rebound hyperglycemia in non-diabetic subjects
Hepatol 2 , 423433 (2005)
We think you'll like Use previous and next buttons to navigate the slides of the We think you'll like Product Carousel
Remarkably, the GO@GSH-FA treatment group exhibited a significant amelioration in cell viability compared to the OGD/R group, with cell viability restored to levels comparable to the control group, suggesting that the treatment effectively reversed the detrimental effects of OGD/R (Figure 4C)
US$ 24.53
US$ 24.95
US$ 26.69
